Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: How to predict the efficacy of sunitinib before treatment initiation was less known.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Zhang Y, Chen L, Wang W, Jin K, Yuan B,
Keywords: sunitinib, computed tomography, efficacy prediction,
Introduction: Peptide receptor radionuclide therapy (PRRT) is an established treatment of metastatic neuroendocrine neoplasms (NEN) with positive effects on both progression free survival (PFS) and overall survival (OS). Only a few previous studies have investigated the effect of a second series and hence a retreatment with PRRT.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Zacho M, Iversen P, Villadsen G, Arveschoug A, Grønbæk H,
Keywords: neuroendocrine tumor, gastropancreatic tumors, bronchopulmonary tumors, peptide receptor radionuclide therapy,
Introduction: CT-Guided HDR Brachyterapy is a new method used for liver metastases treatment.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Kieszko D, Cisek P, Kolasińska-Ćwikła A, Bednarczuk T, Nowicki M,
Keywords: advanced non-resectable neuroendocrine neoplams, CT image guided HDR Brachytherapy,
Introduction: Pretherapeutic 68Gallium-DOTA-(0-Tyr3)-octreotate (68Ga-DOTATATE) PET standardised uptake value (SUV) has shown conflicting results in the prediction of tumour response to radionuclide therapy.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Ladwa R, Pattison D, Smith J, Goodman S, Burge M,
Keywords: 68Ga-DOTATATE PET-CT, SUV parameters, Tumor response, Somatostatin receptor tumor volume,
Introduction: Immuno check-point inhibitors development in grade 1-2 NENs is limited by low mutation tumor load and PD-1/PDL-1 expression. The combination of an PDL-1 and CTLA-4 inhibitors could increase the probability of success in this setting. In high grade NENs the rational for immunotherapy is stronger based on experiences in small cell lung cancer.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Hernando-Cubero J
Authors: Hernando-Cubero J, Manzano J, Benavent M, Lopez C, Teulé R,
Keywords: Durvalumab, Tremelimumab, Neuroendocrine, Immunotherapy,